Hotline Archive
Below are links to hotlines published prior to 1999.
- Etanercept (Enbrel) Label Updated Following Post-marketing Infectious Events (07/99)
- Rofecoxib (Vioxx) (07/99)
- Zinaxin (Ginger Root) (05/99)
- FDA Approval of Prosorba Immmunoadsorption Column (05/99)
- Update on New Agents for Rheumatoid Arthritis: Celebrex, Enbrel, Arava (03/99)
- Preliminary FDA Approval of Etanercept (Enbrel) (09/98)
- Preliminary FDA Approval of Leflunomide (Arava) (08/98)
- Minocycline Treatment for Scleroderma (05/98)
- Hyaluronic Acid Treatment for Osteoarthritis (07/97)
- Glucosamine Sulfate and Chondroitin Sulfate for Osteoarthritis (01/97)
- Treatment of RA with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications (05/96)
- Treatment of RA by Immunization with White Blood Cells (02/96)
- Alendronate (Fosamax) Trials in Osteoporosis (10/95)
- Cyclosporine and Methotrexate in Rheumatoid Arthritis (07/95)
- Lymphoproliferative Disease in Patients with Autoimmune Disease on Low-Dose Methotrexate (06/95)
- Minocycline as Treatment in Rheumatoid Arthritis (01/95)
- Risk of Renal Failure With Angelesic Use (12/94)
- Is There a Link Between Arthritis and Cardiovascular Disease? (11/94)
- Cartilage Growth Factor (TGF-ß) In Osteoarthritis (03/94)
- Why the Bones Break (02/94)
